Abstract Erythropoietin ( Epo) controls the prolifera-urine of aplastic patients. From tryptic fragments of this urinary Epo, Epo DNA probes were synthesized tion, differentiation and survival of the erythroid progenitors. Epo exerts its effects by binding to a cell for the isolation and cloning of the human Epo gene [2, 3] . The use of recombinant Epo (epoetin) to treat surface receptor. The Epo receptor includes a p66 chain, which is dimerized upon Epo activation, and the anaemia of chronic renal failure followed shortly thereafter showed that Epo stimulation was not necessary for the it seems to act mainly as a survival factor. Epo is commitment of the progenitors in the erythroid lineage. synthesized largely by the kidney and the liver, and Indeed, both burst-forming units-erythroid (BFU-E) sequences required for tissue-specific expression have and CFU-E were produced to normal levels in mice been localized in the Epo gene. A 3∞ enhancer is that lacked either Epo or Epo receptor genes [7, 8] , responsible for hypoxia-inducible Epo gene expression.
Jak2 tyrosine kinase. Jak2 activation leads to the Role of Epo in erythropoiesis tyrosine phosphorylation of several proteins, including the Epo receptor itself. Different intracellular pathways
Cultures of haematopoietic progenitors in semi-solid are activated: Ras/MAP kinase, phosphatidylinositol media have shown that the main targets of Epo are 3-kinase and STAT transcription factors. However, the the late erythroid progenitors, especially the colonyexact mechanisms by which the proliferation and/or forming units-erythroid (CFU-E ) [5, 6 ] . Epo and Epo differentiation of erythroid cells are regulated after receptor gene disruptions in mice confirmed that Epo Epo stimulation are not known. Target disruption of stimulation was essential for the survival and proliferaboth Epo and Epo receptors showed that Epo is not tion of CFU-E [7, 8] . Moreover, these experiments involved in the commitment of the erythroid lineage;
showed that Epo stimulation was not necessary for the it seems to act mainly as a survival factor. Epo is commitment of the progenitors in the erythroid lineage. synthesized largely by the kidney and the liver, and Indeed, both burst-forming units-erythroid (BFU-E) sequences required for tissue-specific expression have and CFU-E were produced to normal levels in mice been localized in the Epo gene. A 3∞ enhancer is that lacked either Epo or Epo receptor genes [7, 8] , responsible for hypoxia-inducible Epo gene expression.
thereby demonstrating that Epo is not involved in the Hypoxia-induced factor-1 (HIF-1) protein binds to determination of the erythroid lineage. Thus, the overthis enhancer. In addition to anaemia of renal failure, all action of Epo appears to be rescue from apoptosis, the indication for treatment with epoetin has been sustainment of cell proliferation and induction of erythextended to the anaemia of chronic diseases.
roid-specific proteins at the CFU-E level.
Introduction
of Epo in these cells seems to be the inhibition of apoptosis. HCD-57 cells infected with a retroviral Erythropoietin (Epo), a 34 kDa glycoprotein hormone, vector encoding either Bcl-2 or Bcl-X L remain viable was the first haematopoietic growth factor to be cloned. in the absence of Epo. However, Epo is still required The role of Epo is to control red blood cell production for the proliferation of these cells [17] . through the promotion of survival, proliferation and differentiation of the erythroid progenitors in the bone marrow. Epo is the only haematopoietic growth factor Epo receptor whose production is regulated by hypoxia. Epo was purified successfully by Miyake et al. [1] from the Due to the very low concentrations of circulating Epo hormone was produced in 1985 [2, 3] [20, 22, 23] . Epo receptors were also detected in mega-The crystal structure of the complex of one of these agonist peptides with the extracellular domain of p66 karyocytic cells [24, 25] , in murine placenta [26 ] , in endothelial cells [27, 28] and in cells with neural charac-shows that a peptide dimer induces the dimerization of p66 [43] . The covalent dimerization of this peptide teristics [29] .
The Epo receptor (p66) was cloned by an expression recently was shown to increase its potency [44] . An activating mutation in the extracellular domain strategy from a cDNA library of murine erythroleukaemic cells [30] . Transfection of p66 induces the of p66, changing the Arg129 residue to Cys, constitutively activates the Epo receptor [45] and induces proliferation of most growth factor-dependent haematopoietic cells after Epo stimulation. Chemical Epo leukaemia in mice [46, 47] . The Cys residue is held in a disulphide bond, which is believed to homodimerize cross-linking to the cell surface of erythroid cells has revealed the association of Epo with two molecules of the p66 molecule [48] . The mutation of other amino acids (Glu132 or Glu133) to Cys in the same region 85 and 100 kDa, respectively (reviewed in [18] ). The identity of these proteins, their relationship with p66 of p66 also produces constitutively activated Epo receptors [49] . and their role in the mechanism of action of the Epo receptor are unclear. These proteins are associated with p66 but are not recognized by anti-p66 antibodies Epo-induced intracellular signalling [31] . Expression of truncated forms of p66 in transfected haematopoietic cells does not modify the apparent molecular mass of p85 and p100 [32, 33] . The same Like all the receptors of the haematopoietic receptor family, the Epo receptor does not possess endogenous observation was made using the TF-1 cell line, which naturally expresses a truncated Epo receptor [34] , tyrosine kinase activity. Despite this fact, Epo stimulates the rapid tyrosine phosphorylation of a number thereby confirming that these proteins do not derive from the p66 cloned protein. Thus, the identity of of proteins. The first step of intracellular signalling is the activation of the Jak2 tyrosine kinase, which is these Epo-cross-linked proteins needs to be determined in order to better understand the structure of the Epo constitutively associated with the Epo receptor [50] ( Figure 1 ). Jak2 is known to associate with the Epo receptor.
In common with most haematopoietic growth factor receptor in a region close to the transmembrane, and deletion of this part of the Epo receptor inhibits Eporeceptors, p66 belongs to the cytokine receptor family. The extracellular domain of these receptors possesses induced cellular proliferation [51] .
Among the proteins phosphorylated on tyrosine a conserved domain of~200 amino acids, which derives from the duplication of a 100 amino acid residues in response to Epo is the Epo receptor itself [13, [52] [53] [54] . Eight tyrosines located in the cytoplasmic subdomain with a type III fibronectin structure [35] . These receptors exhibit a WSXWS sequence in the domain of the Epo receptor are probably phosphorylated after Epo stimulation. These phosphorylated tyrosecond (membrane-proximal ) subdomain and two pairs of cysteines in the first subdomain. The two pairs sines are in turn docking sites for various intracellular proteins containing Src homology 2 (SH2) domains. of cysteines are held by disulphide bonds. The WSAWS sequence of the Epo receptor appears to be necessary After binding, these proteins subsequently can be tyrosine phosphorylated and activated. Therefore, stimulafor the correct folding and/or transport of p66 at the cell surface. Indeed, mutations affecting each of tion by Epo leads to localization close to the receptor and the plasma membrane of different activated molethe WS motifs reduce or inhibit p66 cell surface expression [36, 37] .
cules which participate in downstream signal transduction ( Figure 2 ). Epo appears to activate the Epo receptor by dimerization of the p66 protein. Dimers of the extracellular
The Ras/MAP kinase pathway is activated by Epo [55, 56 ] . This pathway is involved in cell proliferation domain of p66 bound to one Epo molecule have been demonstrated [38] . The affinity of each binding site in response to Epo [57] .
A direct association between phosphatidylinositol was determined: the first Epo receptor molecule bound Epo with a fairly high affinity (K d 1 nM ), whereas the 3-kinase (PI 3-kinase) and the Epo receptor has been shown [58-61], which involves the SH2 domains of second Epo receptor molecule appeared to bind to the complex with a low affinity (K d~2 mM ). Direct the p85 subunit of the PI 3-kinase and the last tyrosine Epo is the subject of controversy. Whereas a correlation between STAT5 activation and cell proliferation has been described by some groups Two tyrosine phosphatases, SHP-1 and SHP-2, play a role in Epo-induced signalling. SHP-2 is phosphorylated on tyrosine in response to Epo and associates with the second tyrosine residue of the Epo receptor ( Tyr401); SHP-2 seems to play a positive role in stimulating cell proliferation [76 ] . In contrast, SHP-1 plays a negative role in Epo-induced signal transduction; its association with Tyr429 of the Epo receptor leads to the dephosphorylation of Jak2 [77] . Interestingly, De La Chapelle et al. [78] described a familial erythrocytosis in which a truncated Epo receptor was found in the polycythaemic members of the family; these truncated receptors were shown to be hypersensitive to Epo probably because they lacked the SHP-1-binding site.
The role of tyrosine phosphorylation of the Epo receptor completely devoid of tyrosine residues is still able to transduce a proliferative signal; some reports have found that these Epo receptors were less sensitive of the Epo receptor [62] . An alternative pathway for to Epo [33, 68, 69, 79] , whereas this decrease in sensitivthe activation of PI 3-kinase has been described ity has not been mentioned by others [70] [71] [72] . recently, which involves the tyrosine phosphorylation Expression of b-globin can be obtained in Ba/F3 cells of the adaptor protein IRS2 and its subsequent associafter transfection of mutant Epo receptors that do not ation with PI 3-kinase; this mode of activation therecontain any tyrosine residue [33, 79] . However, in fore does not require the interaction of PI 3-kinase normal erythroid progenitors, the last tyrosine of the with the Epo receptor tyrosines [63] .
Epo receptor cytoplasmic domain ( Tyr479) seems to The STAT (signal transducer and activator of tranbe required for erythroid colony formation [80, 81] . scription) pathway plays a major role in cytokineThis Tyr479 is sufficient to obtain erythroid differentiinduced signalling [64] . Epo activates both STAT5A ation of progenitors from fetal liver [80] ; similar and STAT5B [65-67]. The two first tyrosines of the properties were reported recently by Longmore et al. intracellular domain of the Epo receptor ( Tyr343 and in an in vivo model [82] . Tyr401) are responsible for STAT5 fixation and activaAnother haematopoietic growth factor receptor tion [68] [69] [70] [71] [72] . Despite a large number of publications, the precise role of STAT5 in the signalling induced by belonging to the tyrosine kinase receptor family, the
while it accumulates rapidly following exposure to the Epo receptor and could activate and phosphorylate the Epo receptor, thus enhancing erythroid cell prolif-hypoxia [100].
The mechanism of regulation by hypoxia was first eration and differentiation [83] . In addition, this cooperation between c-kit and Epo receptors has been studied in hepatoma cells, Hep3B or HepG2, which produced Epo. It was shown further that identical found to be essential for the normal erythroid differentiation of progenitors derived from fetal liver [81] . The responses could be obtained in a large array of nonEpo-producing cells and that the system of gene regulaexact mechanism of interaction between these two receptors is, however, unclear; they appear to act tion by oxygen was widespread [101, 102] . Many genes have now been identified as targets of HIF-1 function. through distinct intracellular signals [84] .
In addition to Epo, these include vascular endothelial growth factor ( VEGF ), several glycolytic enzymes,
Regulation of Epo production
glucose-transporter 1, inducible nitric oxide synthase, haem oxygenase and transferrin [103] . These recent data strengthen the idea that cellular response to Epo production is regulated by hypoxia, which leads to an increase in Epo gene transcription [85] ; there are hypoxia is an important physiological process and that a similar mechanism for oxygen sensing and signal no stores of pre-formed Epo. Control of Epo gene expression involves complex interactions between transduction must be shared by many tissues and cells [104] . However, oxygen-sensing mechanisms are still DNA and nuclear proteins. A 50 bp hypoxia-inducible enhancer has been defined approximately 120 bp 3∞ to not completely understood. According to the model of Hep3B cells, a single cell type can apparently sense the polyadenylation site, and is responsible for hypoxia-inducible Epo gene expression [86] [87] [88] . Mice hypoxia and respond by increasing Epo RNA levels [105] . It was proposed that the oxygen sensor is a transgenic for a construct containing the Epo gene and this 3∞ enhancer harboured hypoxia-inducible Epo gene haem protein that changes its conformation depending on the binding of oxygen to its haem moiety. The iron expression in the liver.
The 3∞ enhancer contains three different segments atom of haem can be replaced by cobalt, thereby mimicking the hypoxic state [106 ] . The exact mecha- [89] . A conserved sequence located near the 5∞ end of the enhancer is the binding site for a novel transcription nism of activation of transcription factors by hypoxia, however, remains to be determined. factor designated hypoxia-induced factor-1 (HIF-1) [90, 91] . The middle segment is less conserved between species, but seems to play a role in the inducibility of
Indications of Epo treatment outside the setting of
both the human and the murine Epo enhancers [92] .
renal anaemia
The third part corresponds to 3∞ DNA sequences, which are binding sites for the hepatocyte nuclear factor 4 (HNF-4) [93] . Furthermore, the C-terminal Epoetin has been used for the correction of anaemia of renal failure. In some cases, this treatment has been portion of HIF-1 specifically binds to p300 and overexpression of p300 enhances hypoxic induction [94] . extended to anaemia of chronic diseases. In these disorders, cytokines involved in the inflammatory Thus, it is likely that hypoxia induces the formation of a large complex of proteins directly or indirectly response inhibit both Epo synthesis and erythroid colony formation in vitro [107, 108] . It was shown bound to the enhancer, which in turn transduce a signal to the Epo promoter, thereby permitting gene recently that interferon-c (IFN-c) down-regulates the SCF receptor and the Epo receptor at the surface of transcription [95] .
The identification of HIF-1 as a DNA transcrip-the erythroid progenitors, thus leading to reduction of the survival and growth of these cells and eventually tional complex has been a critical step towards understanding the enhancer function. Affinity purification to apoptosis of these progenitors [109] . Further studies showed that IFN-c induced the concomitant expression showed that HIF-1 is composed of two subunits [89, 96 ] . Molecular cloning of HIF-1 by Wang and of Fas and Fas ligand at the surface of the erythroid progenitors, thereby leading to apoptotic cell death Semenza [97] showed that the DNA-binding complex was composed of two basic helix-loop-helix proteins [110] . More work is needed to understand if physiological interactions between the intracellular signals called HIF-1a and HIF-1b. HIF-1b previously had been identified as the aryl hydrocarbon nuclear recep-induced by Epo and the Fas system play a role in erythroid cell survival. About half of anaemias in tor translocator (ARNT ), a molecule involved in the xenobiotic response [98] . In contrast, HIF-1a was a patients with chronic anaemia of cancer can be corrected with epoetin. The appropriate selection of new member of this family of proteins. In hypoxic conditions, the levels of the mRNAs encoding either patients and cost-benefit ratios are major problems associated with these clinical applications of the HIF-1a or HIF-1b were not altered, suggesting that the activity of the HIF-1a-ARNT complex is regulated hormone.
Chemical modification of the Epo molecule to by a post-transcriptional mechanism and a conformational change after recruitment of the ARNT trans-improve its stability and specific activity would be interesting, provided that no antibodies arise against 
